These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1698543)

  • 1. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.
    Kimmig A; Gekeler V; Neumann M; Frese G; Handgretinger R; Kardos G; Diddens H; Niethammer D
    Cancer Res; 1990 Nov; 50(21):6793-9. PubMed ID: 1698543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis.
    Ramoni C; Dupuis ML; Cenciarelli C; Ciccolini F; Cianfriglia M
    Ann Ist Super Sanita; 1990; 26(3-4):433-9. PubMed ID: 1982604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
    Hill AB; Beck WT; Trent JM
    Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.
    Yusa K; Tsuruo T
    Cancer Res; 1989 Sep; 49(18):5002-6. PubMed ID: 2569930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
    Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
    Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
    Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
    Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.
    Kavallaris M; Madafiglio J; Norris MD; Haber M
    Biochem Biophys Res Commun; 1993 Jan; 190(1):79-85. PubMed ID: 8093660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
    Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The over-expression of P-glycoprotein in K-562 and DAUDI cells, is associated with a high susceptibility to NK and LAK cells.
    Dupuis ML; Ramoni C; Yassen A; Samoggia P; Tombesi M; Caserta M; Cianfriglia M
    J Biol Regul Homeost Agents; 1991; 5(4):137-41. PubMed ID: 1687102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment-induced multidrug resistant human ovarian cancer cells.
    Mazzoni A; Trave F; Fabbri M; Leto G; Ghidoni R
    Anticancer Res; 1991; 11(6):2181-5. PubMed ID: 1776860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
    Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S
    Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
    Zheng YJ; Zhang J; Wang SM; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
    Harker WG; Slade DL; Dalton WS; Meltzer PS; Trent JM
    Cancer Res; 1989 Aug; 49(16):4542-9. PubMed ID: 2568172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
    Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P
    Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
    Lin TH; Chu TM
    Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.
    Cass CE; Janowska-Wieczorek A; Lynch MA; Sheinin H; Hindenburg AA; Beck WT
    Cancer Res; 1989 Nov; 49(21):5798-804. PubMed ID: 2790792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.